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Abstract We present a Norwegian family with familial
hemiplegic migraine (FHM) with possibly four affected in
three generations. The family had a point mutation in the
ATP1A2 gene that caused a change of the amino acid
valine to methionine (V628 M). The symptoms were pure
FHM with intra- and interindividual variability, and epi-
lepsy is not part of the clinical picture. Attacks could be
provoked by physical activity. The proband had prolonged
attacks of FHM, and was hospitalized due to such an attack
provoked by a minor head trauma. The initial management
was conservative, but due to persistence of the hemiplegia
on day 9, a continuous nimodipine infusion was initiated in
order to prevent cerebrovascular vasospasm. However, the
nimodipine infusion worsened the patient’s symptoms and
possibly provoked a generalized tonic–clonic seizure due
to vasodilatation and reduced cerebral blood flow. The
MRI showed cortical edema and the SPECT showed
reduced perfusion on the contralateral side of the hemi-
plegia. We conclude that nimodipine is contraindicated in
the management of prolonged FHM attacks, and recom-
mend conservative management and supplement of suffi-
cient intravenous fluid in nauseated patients in order to
avoid hypovolemia.
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Introduction
Familial hemiplegic migraine (FHM) is an autosomal
dominant rare type of migraine with aura characterized by
some degree of hemiparesis [1]. FHM1, FHM2 and FHM3
are caused by mutations in the ion-channel genes CAC-
NA1A, ATP1A2 and SCN1A, respectively [2–4]. Some
FHM families have mutations in yet unidentified genes.
The majority of FHM families have pure FHM, but cere-
bellar ataxia is frequent in FHM families with mutation in
the CACNA1A gene [5, 6].
We present a Norwegian family with a V628 M muta-
tion in the ATP1A2 gene (Fig. 1). One of the affected had
prolonged FHM attacks and a single generalized clonic–




A 16-year-old male was referred to the neurological ward
on a hot summer day due to a prolonged attack of FHM.
The patient had played soccer and shortly after heading a
ball he experienced a left-sided homonymous hemianopsia,
followed by left-sided sensory symptoms and motor
weakness, and then a contralateral migrainous headache.
From the age of 2 years he experienced several attacks
of sudden drowsiness, nausea and headache. Most attacks
were preceded by head trauma and were interpreted as
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commotio. At the age of 6 years he also experienced motor
weakness and reduced coordination of the hand during
attacks, and at the age of 9 years this was followed by
dysphasia and somnolence. Several CT-scans of the brain
were normal. At the age of 10 years he had the diagnosis
FHM after a prolonged attack with visual disturbances,
scotoma, sensory symptoms, motor weakness, aphasia,
somnolence and contralateral headache. The aphasia per-
sisted for 3 weeks. The CT scan and the MRI were normal.
He was discharged with 75 mg acetylsalicyl acid daily, and
160 mg propranolol daily. After initiation of the prophy-
lactic treatment, the attack frequency 1–2 times per year
was unchanged, but the duration of the aura symptoms
and headache was reduced to 12 and 24–36 h duration,
respectively.
Prior to hospital admission the patient barely drank or
ate anything for 5 days due to nausea and severe
migrainous headache. At first, he received treatment with
metoclopramide, paracetamole and ketobemidon and
1,000 ml i.v. saline daily. CT scanning of the brain was
normal. Blood test including blood count, B-12, creatine
kinase, electrolytes, liver status, TSH, antinuclear anti-
bodies, anticardiolipin antibodies and rheumatoid factor
were all normal. The symptoms persisted with fluctuating
intensity, and worsened the 9th day. Due to fear of vaso-
constriction and migraine infarction, several measures were
evaluated including continuous conservative management
and verapamil treatment. After external advice continuous
infusion of intravenous nimodipine 5–10 ml/h (dose) was
initiated. The patient’s symptoms worsened within hours,
and the following morning he had a generalized tonic–
clonic seizure. Nimodipine infusion was stopped immedi-
ately. Total infusion dose was then 16 mg. An acute MRI
showed mild swelling of the right parietal lobe (Figs. 2, 3).
Diffusion weighted images showed ischemic changes but
not infarction. The EEG showed diffuse slowing over the
right hemisphere without paroxystic activity. The patient
was given oral metylprednisolone and oral valproate. The
symptoms gradually improved. On day 22 he continued to
have some degree of hemiparesis along with apraxia,
homonymous hemianopsia and mild cognitive failure, i.e.,
25 of 30 points on the mini mental state examination
(MMSE), and mildly impaired memory score and moder-
ately impaired construction score on the Cognistat. At that
time a single photon emission computed tomography
(SPECT) showed reduced perfusion in the right hemi-
sphere, predominantly in the temporal and parietal lobe
(Fig. 4). The patient was discharged after 3 weeks hospi-
talization and re-admitted 4 weeks later on day 55. At that
Fig. 2 T2-weighted MRI on day 10 showing hyperintensity and











Fig. 1 The pedigree, the arrow indicate the proband, squares are
men and circles are women, filled symbols are affected, and forward
slash indicate deceased
Fig. 3 Apparent diffusion coefficient (ADC) map on day 10 showing
restricted diffusion in the right temporal and parietal regions
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time he suffered from dizziness and memory deficits.
Clinical examination disclosed a partial homonymous
hemianopsia, and the MMSE score was 29 due to one point
lost on the memory task. The MRI was normalized, while
the SPECT and EEG were unchanged. The patient was
discharged few days later. He started at school shortly after
and managed to follow lectures. After 5 months he par-
ticipated in a running competition. This provoked an attack
of 1-week duration, and he was advised to refrain from
intensive physical activity.
Family history
Grandmother. The proband’s deceased grandmother on the
mother’s side was reported to have had attacks of hemi-
plegia, but never had epileptic seizures.
Mother. The proband’s mother is 49 years old. She
experienced her first attack at the age of 10 years. It usually
started with unilateral sensory symptoms followed by
unilateral hemiparesis and then she got a contralateral
headache. Initially the attacks lasted up to 4 days and
occurred from two to four times every month. The attack
duration and frequency declined during adolescence, and
she experienced her last attack at age 38 years. The attacks
were often provoked by physical activity and the affected
side varied between attacks. She had never had epileptic
seizures.
Brother. The proband’s elder brother is 18 years old. He
experienced his first attack at the age of 13 year and had
not more than 15 attacks since then. The attacks usually
start with dizziness followed by homonymous visual dis-
turbances, unilateral sensory symptoms, aphasia and
unilateral weakness and then a contralateral headache. The
aura symptoms usually last from 1 to 6 h, while the
headache last up to 24 h. The aura symptoms change side
from attack to attack. The attacks are often provoked by
physical activity. He never had any epileptic seizures.
Genetic testing
Genetic testing showed a point mutation in exon 14 of the
ATP1A2 gene. The nucleotide 1987 G [ A substitution
causes a change of the amino acid valine to methionine
(V628 M). Both 16-year-old patients and mother had the
mutation, while the elder brother was not tested.
Discussion
We report a Norwegian family with FHM2 in possibly
three generations. The phenotype–genotype correlation of
the identified mutation (V628 M) is strengthened by the
fact that it has also been reported in a Turkish family [7].
The Norwegian family had attacks of pure FHM, with
pronounced intra-familial variation in frequency, severity
and duration of attacks. Physical activity provoked attacks
in the affected alive, and mild head trauma provoked
attacks in the proband. The symptomatology and variation
are similar to that described in the Turkish family [7].
Epileptic seizures were not reported in Norwegian nor the
Turkish family. Mutations in the ATP1A2 gene usually
cause pure FHM, but alternating hemiplegia of childhood,
benign familial infantile convulsions, cerebellar symptoms,
severe episodic neurological deficits and mental retardation
have also been reported [8–18].
The hypovolemia caused by dehydration and arterial
hypotension probably added to sustain the prolonged FHM
attack, but these factors alone has not previously been
sufficient to cause a generalized tonic–clonic seizure in the
proband. The seizure is most likely caused by nimodipine,
as the proband and his mother both noticed worsening of
the aura symptoms after initiation of the intravenous
nimodipine infusion. Nimodipine is a calcium-channel
blocker that dilates cerebral vessels and it is used to prevent
delayed cerebral ischemia following subarachnoid hemor-
rhage [19]. In theory nimodipine might prevent the
vasospasm of FHM by lowering Ca2?-influx. However, the
continuous intravenous infusion of nimodipine probably
aggravated the arterial hypotension, a known side effect.
This caused additional hypoperfusion and hypoxia in the
right hemisphere, which lead to a generalized tonic–clonic
seizure and a secondary edema as shown on MRI and
SPECT (for details see above). We conclude that nimodi-
pine is contraindicated in the management of prolonged
FHM attack, and recommend conservative management
Fig. 4 99 m Tc-HMPAO-SPECT on day 22 showing cerebral blood
flow hypoperfusion in the right hemisphere, predominantly in the
temporal and parietal regions
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except from supplement of sufficient intravenous fluid in
nauseated patients in order to avoid hypovolemia.
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